Saturday 17 October 2026
Export MGRX’s income statement to Excel — free account
Mangoceuticals, Inc.
MGRX Healthcare Health Information Services
Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024. In the quarter to June 2026, revenue fell 59.1%, EPS grew 84.2% and free cash flow grew 79.3%, each against the same quarter a year earlier.
0.30
0.02
−6.25%
Follow MGRX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 3.98 | 2.07 | 0.52 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 65.55 | 16.80 | 6.15 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 1 | 1 | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | 55.06 | 58.99 | 61.70 | 54.91 | |||||
| EBT | — | — | — | — | — | 0 | (2) | (9) | (9) | (21) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | (22,450.56) | (1,259.38) | (1,413.74) | (4,527.08) | |||||
| Net income | — | — | — | — | — | 0 | (2) | (9) | (9) | (21) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 1 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.01 | 0.68 | 0.31 | 0.05 | ||||
| Earnings | — | — | — | — | — | 0.00 | (2.77) | (8.55) | (4.84) | (2.17) | |||||
| Cash flow | — | — | — | — | — | 0.00 | (1.87) | (6.51) | (2.46) | (0.58) | |||||
| Capex | — | — | — | — | — | 0.00 | (0.06) | 0.00 | 0.03 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | 0.00 | (1.93) | (6.52) | (2.42) | (0.58) | |||||
| Book value | — | — | — | — | — | 0.00 | 0.85 | 0.72 | 7.05 | 1.51 | |||||
| Shares, m | — | — | — | — | — | 17 | 1 | 1 | 2 | 10 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 6.39 | 7.78 | 16.34 | |||||
| P/B | — | — | — | — | — | — | 70.38 | 6.03 | 0.34 | 0.49 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 5.38 | 7.68 | 13.08 | |||||
| EV/FCF | — | — | — | — | — | — | (31.57) | (0.56) | (0.99) | (1.03) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (1) | (7) | (5) | (6) | ||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | — | |||||
| Free cash flow | — | — | — | — | — | 0 | (1) | (7) | (5) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | 0 | 1 | (1) | 1 | ||||
| Total debt | — | — | — | — | — | 0 | 0 | — | — | — | |||||
| Net debt | — | — | — | — | — | 0 | (1) | (1) | 0 | (1) | |||||
| Shareholders’ equity | — | — | — | — | — | 0 | 1 | 1 | 14 | 15 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (389.53) | (896.98) | (106.03) | (131.23) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (16,094.45) | (35.88) | (82.19) | |||||
| ROE | — | — | — | — | — | 0.00 | (669.04) | (1,326.67) | (118.29) | (141.66) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026
Charts ten years each
Mangoceuticals, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RNLXY Renalytix plc - Sponsored ADR | $17.2M | — (loss-making) | — | +13.73% (above 0%: growing) | n/m | +17.96% (above 0%: growing) | 19.16% | (783.91%) | Compare |
| BFRG Bullfrog AI Holdings Inc. | $9.9M | — (loss-making) | — | +2,054.00% (above 0%: growing) | n/m | −5.67% (below 0%: shrinking) | 49.63% | (658.82%) | Compare |
| ETAOF ETAO International Co., Ltd. | $9.8M | — (loss-making) | — | — | n/m | +37,595.70% (above 0%: growing) | — | 0.00% | Compare |
| HCTI Healthcare Triangle, Inc. | $7.4M | 0.0× | — (loss-making) | +158.38% (above 0%: growing) | n/m | +67.48% (above 0%: growing) | 22.48% | (44.28%) | Compare |
| MGRX Mangoceuticals, Inc. | $7.1M | — (loss-making) | — | −59.07% (below 0%: shrinking) | n/m | +79.27% (above 0%: growing) | 64.24% | (1,501.45%) | |
| HLTHQ Cue Health Inc. | $6.9M | — (loss-making) | — (loss-making) | −87.19% (below 0%: shrinking) | n/m | +50.55% (above 0%: growing) | (90.14%) | (792.13%) | Compare |
| ZCMD Zhongchao Inc. | $6.2M | — (loss-making) | — | +20.44% (above 0%: growing) | −550.00% (below 0%: shrinking) | +191.85% (above 0%: growing) | 41.67% | 0.00% | Compare |
| ACON Aclarion, Inc. | $5.6M | — (loss-making) | — (loss-making) | +30.57% (above 0%: growing) | n/m | −41.41% (below 0%: shrinking) | 32.94% | (11,506.75%) | Compare |
| VSEED VSee Health, Inc. | $2.8M | — (loss-making) | — (loss-making) | +48.02% (above 0%: growing) | n/m | −257.62% (below 0%: shrinking) | 13.20% | (172.69%) | Compare |
| Median of peers | $7.2M | — | — | +30.57% | — | +34.25% | 22.48% | (415.75%) |
Mangoceuticals, Inc. (MGRX) key facts
- Concern: Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024.
- Mangoceuticals, Inc. (MGRX) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MGRX traded at $0.30, a market capitalization of $7.1 million.
- Return on equity was −141.7% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −2.14 (distress zone) for fiscal 2025.